ReviewNeurosurgery2015
Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.
Review in Neurosurgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Timing of Concurrent Chemoradiation in Patients With High-Grade Glioma in the Era of the Stupp Protocol.Frontiers in oncology · 2019Pooled it
- Early Initiation of Radiation Therapy Improves Survival in Elderly Patients With Glioblastoma.Neurosurgery · 2026Article
- Timing of adjuvant chemoradiotherapy after resection and survival in glioblastoma: a single-centre cohort analysis.Journal of neuro-oncology · 2026Article
- Unlocking the Potential of Ultra-High Dose Fractionated Radiation for Effective Treatment of Glioblastoma in Mice.Journal of Cancer · 2024Article
- Unlocking the potential of ultra-high dose fractionated radiation for effective treatment of glioblastoma.Research square · 2023Article
- Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?Cancers · 2022Review
- Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy.Nanomaterials (Basel, Switzerland) · 2022Article
- Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells.International journal of molecular sciences · 2021Article
- The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence.International journal of molecular sciences · 2021Review
- Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable.Diagnostics (Basel, Switzerland) · 2020Article
- Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.PloS one · 2020Article
- Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.Molecules (Basel, Switzerland) · 2019Review
- Newly Diagnosed Glioblastoma: A Review on Clinical Management.Oncology (Williston Park, N.Y.) · 2019Review
- Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.Journal of neuro-oncology · 2017Article
- The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.Journal of hematology & oncology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
abbreviationsEORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of CanadaGBM, glioblastomaOS, overall survivalPFS, progression-free survivalSEER, Surveillance, Epidemiology, and End ResultsTMZ, temozolomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.